3/30
06:18 am
fold
Amicus Therapeutics (FOLD) had its "sell (d-)" rating reaffirmed by
Weiss Ratings.
Low
Report
Amicus Therapeutics (FOLD) had its "sell (d-)" rating reaffirmed by
Weiss Ratings.
3/29
01:37 pm
fold
Assessing Amicus Therapeutics (FOLD) Valuation After A Strong 71% One Year Total Return [Yahoo! Finance]
Low
Report
Assessing Amicus Therapeutics (FOLD) Valuation After A Strong 71% One Year Total Return [Yahoo! Finance]
3/15
11:31 am
fold
Assessing Amicus Therapeutics (FOLD) Valuation After Recent Share Price Momentum And DCF Upside [Yahoo! Finance]
Low
Report
Assessing Amicus Therapeutics (FOLD) Valuation After Recent Share Price Momentum And DCF Upside [Yahoo! Finance]
3/12
12:42 pm
fold
Pombiliti (Amicus Therapeutics) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, Forecasts [Yahoo! Finance]
Neutral
Report
Pombiliti (Amicus Therapeutics) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, Forecasts [Yahoo! Finance]
3/10
08:23 am
fold
Genomenon and Amicus Therapeutics Partner to Advance Fabry Disease Awareness and Diagnosis [Yahoo! Finance]
Low
Report
Genomenon and Amicus Therapeutics Partner to Advance Fabry Disease Awareness and Diagnosis [Yahoo! Finance]
3/10
08:23 am
fold
Chris Duke joins RBL LLC leadership team as Operating Partner [Yahoo! Finance]
Low
Report
Chris Duke joins RBL LLC leadership team as Operating Partner [Yahoo! Finance]
3/6
05:40 am
fold
How The Amicus Therapeutics (FOLD) Story Is Shifting Inside BioMarin's Rare Disease Portfolio [Yahoo! Finance]
Low
Report
How The Amicus Therapeutics (FOLD) Story Is Shifting Inside BioMarin's Rare Disease Portfolio [Yahoo! Finance]
3/5
12:28 pm
fold
Amicus Therapeutics Buyout Advances As Valuation Gap Draws Investor Focus [Yahoo! Finance]
Low
Report
Amicus Therapeutics Buyout Advances As Valuation Gap Draws Investor Focus [Yahoo! Finance]
2/23
09:44 am
fold
Amicus Therapeutics: Q4 Earnings Snapshot [Yahoo! Finance]
Low
Report
Amicus Therapeutics: Q4 Earnings Snapshot [Yahoo! Finance]
2/20
04:01 pm
fold
Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates
Low
Report
Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates
2/18
07:46 pm
fold
TD Cowen Cautious on Amicus Therapeutics (FOLD) Despite Positive 2025 Revenue Projections [Yahoo! Finance]
Low
Report
TD Cowen Cautious on Amicus Therapeutics (FOLD) Despite Positive 2025 Revenue Projections [Yahoo! Finance]
2/8
11:43 am
fold
Is Amicus Therapeutics (FOLD) Pricing Reflect Long Term Prospects In Rare Disease Treatments [Yahoo! Finance]
Low
Report
Is Amicus Therapeutics (FOLD) Pricing Reflect Long Term Prospects In Rare Disease Treatments [Yahoo! Finance]
2/8
04:28 am
fold
Assessing Amicus Therapeutics (FOLD) Valuation After Strong 3 Month And 1 Year Shareholder Returns [Yahoo! Finance]
Low
Report
Assessing Amicus Therapeutics (FOLD) Valuation After Strong 3 Month And 1 Year Shareholder Returns [Yahoo! Finance]
2/3
08:00 am
fold
Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026
Low
Report
Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026
2/1
06:25 am
fold
The Right Play On BioMarin Pharmaceuticals [Seeking Alpha]
Low
Report
The Right Play On BioMarin Pharmaceuticals [Seeking Alpha]
1/28
07:29 am
fold
Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Low
Report
Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.